James Crowe
Faculty Member
Last active: 3/31/2019

  1. Structural basis for nonneutralizing antibody competition at antigenic site II of the respiratory syncytial virus fusion protein. Mousa JJ, Sauer MF, Sevy AM, Finn JA, Bates JT, Alvarado G, King HG, Loerinc LB, Fong RH, Doranz BJ, Correia BE, Kalyuzhniy O, Wen X, Jardetzky TS, Schief WR, Ohi MD, Meiler J, Crowe JE (2016) Proc Natl Acad Sci U S A 113(44): E6849-E6858
    › Primary publication · 27791117 (PubMed) · PMC5098655 (PubMed Central)
  2. Recognition of influenza H3N2 variant virus by human neutralizing antibodies. Bangaru S, Nieusma T, Kose N, Thornburg NJ, Finn JA, Kaplan BS, King HG, Singh V, Lampley RM, Sapparapu G, Cisneros A, Edwards KM, Slaughter JC, Edupuganti S, Lai L, Richt JA, Webby RJ, Ward AB, Crowe JE (2016) JCI Insight 1(10)
    › Primary publication · 27482543 (PubMed) · PMC4962875 (PubMed Central)
  3. Phenome-Wide Association Study to Explore Relationships between Immune System Related Genetic Loci and Complex Traits and Diseases. Verma A, Basile AO, Bradford Y, Kuivaniemi H, Tromp G, Carey D, Gerhard GS, Crowe JE, Ritchie MD, Pendergrass SA (2016) PLoS One 11(8): e0160573
    › Primary publication · 27508393 (PubMed) · PMC4980020 (PubMed Central)
  4. Pathogenic Chikungunya Virus Evades B Cell Responses to Establish Persistence. Hawman DW, Fox JM, Ashbrook AW, May NA, Schroeder KMS, Torres RM, Crowe JE, Dermody TS, Diamond MS, Morrison TE (2016) Cell Rep 16(5): 1326-1338
    › Primary publication · 27452455 (PubMed) · PMC5003573 (PubMed Central)
  5. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Sapparapu G, Fernandez E, Kose N, Bin Cao , Fox JM, Bombardi RG, Zhao H, Nelson CA, Bryan AL, Barnes T, Davidson E, Mysorekar IU, Fremont DH, Doranz BJ, Diamond MS, Crowe JE (2016) Nature 540(7633): 443-447
    › Primary publication · 27819683 (PubMed) · PMC5583716 (PubMed Central)
  6. Low frequency of broadly neutralizing HIV antibodies during chronic infection even in quaternary epitope targeting antibodies containing large numbers of somatic mutations. Hicar MD, Chen X, Kalams SA, Sojar H, Landucci G, Forthal DN, Spearman P, Crowe JE (2016) Mol Immunol : 94-103
    › Primary publication · 26748387 (PubMed) · PMC4762738 (PubMed Central)
  7. Long antibody HCDR3s from HIV-naïve donors presented on a PG9 neutralizing antibody background mediate HIV neutralization. Willis JR, Finn JA, Briney B, Sapparapu G, Singh V, King H, LaBranche CC, Montefiori DC, Meiler J, Crowe JE (2016) Proc Natl Acad Sci U S A 113(16): 4446-51
    › Primary publication · 27044078 (PubMed) · PMC4843476 (PubMed Central)
  8. Improving Loop Modeling of the Antibody Complementarity-Determining Region 3 Using Knowledge-Based Restraints. Finn JA, Koehler Leman J, Willis JR, Cisneros A, Crowe JE, Meiler J (2016) PLoS One 11(5): e0154811
    › Primary publication · 27182833 (PubMed) · PMC4868311 (PubMed Central)
  9. Immunogenicity and efficacy of alphavirus-derived replicon vaccines for respiratory syncytial virus and human metapneumovirus in nonhuman primates. Bates JT, Pickens JA, Schuster JE, Johnson M, Tollefson SJ, Williams JV, Davis NL, Johnston RE, Schultz-Darken N, Slaughter JC, Smith-House F, Crowe JE (2016) Vaccine 34(7): 950-6
    › Primary publication · 26772634 (PubMed) · PMC4731299 (PubMed Central)
  10. Human Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein. Hicar MD, Chen X, Sulli C, Barnes T, Goodman J, Sojar H, Briney B, Willis J, Chukwuma VU, Kalams SA, Doranz BJ, Spearman P, Crowe JE (2016) PLoS One 11(7): e0158861
    › Primary publication · 27411063 (PubMed) · PMC4943599 (PubMed Central)